Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).-MedSci.cn

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Kopetz, S; Grothey, A; Yaeger, R; Cuyle, PJAR; Huijberts, S; Schellens, JHM; Elez, E; Fakih, M; Viladot, CM; Peeters, M; Desai, J; Yoshino, T; Ciardiello, F; Wasan, HS; Maharry, K; Christy-Bittel, J; Gollerkeri, A; Van Cutsem, E; Tabernero, J

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (4):

科室
- - 订阅+
  - 更多科室
工具
服务